Skip to content

Psilocybin: all studies

Page 175 of 440: studies 1,741 to 1,750 of 4,392, newest first. Back to the psilocybin overview

Research

A Qualitative Report on the Subjective Experience of Intravenous Psilocybin Administered in an fMRI Environment

Current Drug Abuse Reviews January 9, 2015 Samuel Turton, D.j. Nutt, Robin Carhart-Harris 48 citations

This article documents the phenomenology of psilocybin when given in a novel manner (intravenous injection) and setting (an MRI scanner). The findings of the analysis are consistent with previous published work regarding the subjective effects of psilocybin. There is much scope for further research investigating the phenomena identified in this paper.

DOI: 10.2174/1874473708666150107120930 (opens in new tab) Psilocybin Phenomenology philosophy Hallucinogen Interpretative phenomenological analysis +4

Psilocybin-Occasioned Mystical Experiences in the Treatment of Tobacco Addiction

Current Drug Abuse Reviews January 9, 2015 Albert Garcia‐romeu, Roland R. Griffiths, Matthew W. Johnson 480 citations

Psilocybin-occasioned mystical experiences have been linked to persisting effects in healthy volunteers including positive changes in behavior, attitudes, and values, and increases in the personality domain of openness. In an open-label pilot-study of psilocybin-facilitated smoking addiction treatment, 15 smokers received 2 or 3 doses of psilocybin in the context of cognitive behavioral therapy...

Effect of Psilocin on Extracellular Dopamine and Serotonin Levels in the Mesoaccumbens and Mesocortical Pathway in Awake Rats

Biological and Pharmaceutical Bulletin October 23, 2014 Yuichi Sakashita, Kenji Abe, N. Katagiri et al. 84 citations

Psilocin (3-[2-(dimethylamino)ethyl]-1H-indol-4-ol) is a hallucinogenic component of the Mexican mushroom Psilocybe mexicana and a skeletal serotonin (5-HT) analogue. Psilocin is the active metabolite of psilocybin (3-[2-(dimethylamino)ethyl]-1H-indol-4-yl dihydrogen phosphate). In the present study, we examined the effects of systemically administered psilocin on extracellular dopamine and...

DOI: 10.1248/bpb.b14-00315 (opens in new tab) Serotonin Nucleus accumbens Dopaminergic Microdialysis +4

Psilocybin and Obsessive Compulsive Disorder

Journal of Psychoactive Drugs October 20, 2014 James A. Wilcox 55 citations

Obsessive Compulsive Disorder (OCD) is a psychiatric disorder with considerable morbidity and mortality. This condition disables many individuals and is often refractory to treatment. Research suggests that serotonin plays a role in OCD symptom reduction. We present a case of an individual who successfully used psilocybin, a serotonergic agent, to reduce the core symptoms of OCD for several...

Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction

Journal of Psychopharmacology September 11, 2014 Mary P Cosimano, Matthew W. Johnson, Albert Garcia‐romeu et al. 910 citations

Despite suggestive early findings on the therapeutic use of hallucinogens in the treatment of substance use disorders, rigorous follow-up has not been conducted. To determine the safety and feasibility of psilocybin as an adjunct to tobacco smoking cessation treatment we conducted an open-label pilot study administering moderate (20 mg/70 kg) and high (30 mg/70 kg) doses of psilocybin within a...

14C-Psilocin tissue distribution in pregnant rats after intravenous administration

Functional Foods in Health and Disease July 27, 2014 F. C. P. Law, Grace K. Poon, Y. C. Chui et al. 11 citations

Background: Many species of hallucinogenic mushrooms have been found in the genus Psilocybe. The main psychoactive chemicals of Psilocybe mushrooms are psilocin and its phosphoryloxy derivative, psilocybin. In addition to its psychedelic effects, psilocybin is an effective agent to lift the mood of depressed patients with terminal cancers.Objective: To study the dispositional kinetics of...

DOI: 10.31989/ffhd.v4i6.9 (opens in new tab) Psilocybin Urine Metabolite Pharmacology +2

The effects of psilocybin and MDMA on between-network resting state functional connectivity in healthy volunteers

Frontiers in Human Neuroscience May 27, 2014 Leor Roseman, Robert Leech, Amanda Feilding et al. 293 citations

Perturbing a system and observing the consequences is a classic scientific strategy for understanding a phenomenon. Psychedelic drugs perturb consciousness in a marked and novel way and thus are powerful tools for studying its mechanisms. In the present analysis, we measured changes in resting-state functional connectivity (RSFC) between a standard template of different independent components...

The Effect of Psilocin on Memory Acquisition, Retrieval, and Consolidation in the Rat

Frontiers in Behavioral Neuroscience May 16, 2014 Lukáš Rambousek, Tomáš Páleníček, Karel Valeš et al. 55 citations

The involvement of the serotonin system in the pathophysiology of schizophrenia has been elucidated by experiments with hallucinogens. Application of a hallucinogen to humans leads to changes in perception, cognition, emotions, and induction of psychotic-like symptoms that resemble symptoms of schizophrenia. In rodent studies, their acute administration affects sensorimotor gating, locomotor...

DOI: 10.3389/fnbeh.2014.00180 (opens in new tab) Hallucinogen Memory consolidation Water maze Cognition +2

Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers

Biological Psychiatry April 26, 2014 Rainer Kraehenmann, Katrin H. Preller, Milan Scheidegger et al. 325 citations

BackgroundThe amygdala is a key structure in serotonergic emotion-processing circuits. In healthy volunteers, acute administration of the serotonin 1A/2A/2C receptor agonist psilocybin reduces neural responses to negative stimuli and induces mood changes toward positive states. However, it is little-known whether psilocybin reduces amygdala reactivity to negative stimuli and whether any change...